Join this expert-led discussion to explore the key pathophysiological role of eosinophilic inflammation underlying the variable and evolving clinical manifestations of eosinophilic granulomatosis with polyangiitis (EGPA). This program will highlight the complex clinical challenges of diagnosing EGPA and examine unmet needs within the current treatment paradigm. Developed and offered by AstraZeneca.
Non-CME
